Clinical Trial Update: Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab with capecitabine and radiation therapy for mismatch-repair deficient and Epstein-Barr virus-positive gastric ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Xeloda (capecitabine)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Epstein-Barr Virus Positive, Gastric Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING